NCT00744120

Brief Summary

This follow-up protocol is designed to evaluate participants who have previously been lymphoma patients treated on approved clinical studies of the National Institutes of Health.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
51

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2003

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2003

Completed
4.9 years until next milestone

First Submitted

Initial submission to the registry

August 28, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 29, 2008

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2013

Completed
Last Updated

December 20, 2013

Status Verified

December 1, 2013

Enrollment Period

9.9 years

First QC Date

August 28, 2008

Last Update Submit

December 19, 2013

Conditions

Lymphoma

Keywords

cancer

Outcome Measures

Primary Outcomes (1)

  • Long-term survival following treatment for lymphoma

    Annually

Secondary Outcomes (1)

  • Long-term toxicity possibly attributable to lymphoma or treatment for lymphoma

    Annually

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients, previously entered on NIH study who may be eligible if they have rare, unusual, interesting or unknown conditions that require diagnosis

You may qualify if:

  • Previously treated on an approved NCI/NIH protocols
  • Willing and able to provide informed consent for current NIA protocol
  • Rare, unusual, interesting or unknown condition that requires diagnosis

You may not qualify if:

  • Does not meet the criteria of any previously-approved NIH Protocol.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NIA Clinical Research Unit

Baltimore, Maryland, 21225, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood serum

MeSH Terms

Conditions

LymphomaNeoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Patricia L. Duffey, RN

    National Institute on Aging (NIA)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 28, 2008

First Posted

August 29, 2008

Study Start

October 1, 2003

Primary Completion

September 1, 2013

Study Completion

September 1, 2013

Last Updated

December 20, 2013

Record last verified: 2013-12

Locations

US(1)